Coronavirus (COVID-19) Collection
Pityriasis Rosea Shortly After mRNA-1273 COVID-19 Vaccination
With the increase in rates of vaccination against COVID-19, various cutaneous reactions have been reported after vaccination, including pityriasis rosea (PR) (Catala et al., 2021; Johansen et al., 2021; Marcantonio-Santa Cruz et al., 2021; McMahon et al., 2021). It is easy to overlook because the incidence of PR as a side effect of COVID-19 vaccination is extremely low, accounting for about 0.96% of all cutaneous reactions (McMahon et al., 2021).New style for nasopharyngeal swab with a mask: image-evaluation
COVID-19, caused by SARS-CoV-2, is rapidly spreading worldwide and has become a threat to humankind. Respiratory infectious viruses such as SARS-CoV-2 are transmitted via contact and droplets and have a high secondary attack rate ranging from 3.0%–11.2% in households (Wiersinga et al., 2020). Diagnosis of respiratory infectious virus is performed by collecting specimens from the surface of the respiratory mucosa using nasopharyngeal swabs (Föh et al., 2020; Marty et al., 2020). However, it is a high-risk procedure for healthcare workers because it causes pharyngeal reflexes or sneezing.A case of rapidly progressive upper limb ischemic necrosis in a patient with COVID-19
For more than a year, health systems all over the world have been combating the global coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first described in the city of Wuhan in China, presenting as an atypical infection of the lower respiratory tract.Aortic thrombosis in a patient with COVID-19-associated hyperinflammatory syndrome
A 77-year-old man was admitted for severe PCR-confirmed COVID-19. The patient presented with severe hypoxemia and biological findings suggestive of a hyperinflammatory syndrome: severe lymphopenia in combination with signs of hypercytokinemia (elevated C-reactive protein), coagulopathy (elevated D-dimer levels), and hepatic injury (elevated lactate dehydrogenase) (Webb et al., 2020).Purple urine in a patient after recovery from a SARS-CoV-2 infection
A 96-year-old woman living in a nursing home was admitted to the university hospital Erlangen due to an infection with SARS-CoV-2. She presented with fever, coughing and reduced general condition. Under symptomatic therapy, the patient's condition improved. After 2 weeks, she developed fever again, and her urine turned purple (Figure 1).
